Yazar "Baysak, Sevim" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Clinical and demographic features of hidradenitis suppurativa: A multicentre study of 1221 patients with an analysis of risk factors associated with disease severity
    (Wiley, 2021) Özkur, Ezgi; Karadağ, Ayşe Serap; Üstüner, P.; Aksoy, Bülent; Esme, Pelin; Çalışkan, E.; Akoğlu, Gülşen; Kalkan, Gülhan; Demirseren, Duriye Deniz; Polat, Mualla; Özden, Müge Güler; Kılınç, Fadime; Yalçınkaya İyidal, Ayşegül; Kıvanç Altunay, İlknur; Türkmen, Meltem; Uğurer, Ece; Baysak, Sevim; Fettahlıoğlu Karaman, Bilge; Mammadli, Kifayat; Baykal Selçuk, Leyla; Türkoğlu, Zülal; Atçı, Tolgahan; Didar Balcı, Didem; Özsoy Adışen, Esra; Temel, Berkay; Aktan, Serhat; Gelincik Kaçar, Nida; Gündüz, Kamer; Türel Ermertcan, Aylin; Özdemir, Mustafa; Ünal Çakıter, Alkım; Çölgeçen, Emine; Uçmak, Derya; Kelekçi, Handan Kıymet; Ataseven, Arzu; Durmaz, Koray; Kaya Özden, Hatice; Engin, Berat; Özbek Yazıcı, Sercan; Alpsoy, Erkan
    Background Hidradenitis suppurativa (HS) is a chronic, relapsing and debilitating inflammatory disease associated with profound morbidity. Aim In this multicentre study, we investigated the demographic and clinical features of HS, and determined risk factors of disease severity. Methods In total, 1221 patients diagnosed with HS from 29 centres were enrolled, and the medical records of each patient were reviewed. Results The mean age of disease onset was 26.2 +/- 10.4 years, and almost 70% (n = 849) of patients were current or former smokers. Mean disease duration was 8.9 +/- 8.4 years with a delay in diagnosis of 5.8 +/- 3.91 years. Just over a fifth (21%; n = 256) of patients had a family history of HS. The axillary, genital and neck regions were more frequently affected in men than in women, and the inframammary region was more frequently affected in women than in men (P < 0.05 for all). Acne (40.8%), pilonidal sinus (23.6%) and diabetes mellitus (12.6%) were the most prevalent associated diseases. Of the various therapies used, antibiotics (76.4%) were most common followed by retinoids (41.7%), surgical interventions (32.0%) and biologic agents (15.4%). Logistic regression analysis revealed that the most important determinants of disease severity were male sex (OR = 2.21) and involvement of the genitals (OR = 3.39) and inguinal region (OR = 2.25). More severe disease was associated with comorbidity, longer disease duration, longer diagnosis delay and a higher number of smoking pack-years. Conclusions Our nationwide cohort study found demographic and clinical variation in HS, which may help broaden the understanding of HS and factors associated with disease severity.
  • Küçük Resim
    Öğe
    Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: Real-world data from a retrospective multicenter study
    (Elsevier Science Inc, 2022) Topal, İlteriş Oğuz; Baysak, Sevim; Kıvanç Altunay, İlknur; Kara Polat, Asude; Arıkan, Eylem Emel; Özkur, Ezgi; Aytekin, Sema; Doğan, Bilal; Özkök Akbulut, Tuğba; Topaloğlu Demir, Filiz; Karadağ, Ayşe Serap
    Background: Clinical studies have demonstrated that IL-17A inhibition with secukinumab is effective for clearing the skin of patients with psoriasis and has a favorable safety profile. Objective: The authors aim to determine whether secukinumab is effective and safe for the treatment of moderate-to-severe chronic psoriasis based on clinical experience with this drug. Method: The authors conducted a multicenter retrospective study in nine referral centers and included patients with psoriasis who had received secukinumab between March 2018 to November 2020. Data on demographic characteristics, Psoriasis Area and Severity Index (PASI) scores, and previous treatments were collected from medical records. Patients were evaluated at 12, 24, and 52 weeks with respect to response to treatment and side effects. Results: In total, 229 patients were recruited for the study. A PASI score improvement of ?90 points over the baseline was achieved by 79%, 69.8%, and 49.3% of patients at weeks 12, 24, and 52, respectively. The most common adverse events wereCandida infections and fatigue. In total, 74 (32%) patients discontinued treatment by week 52, including due to adverse events, or secondary ineffectiveness. Study limitations: Retrospective design. Conclusions: These findings suggest that secukinumab therapy is reasonably effective in patients with moderate-to-severe psoriasis. Comorbidities and time length of the disease can affect the response to treatment. The rates of adverse events were high in this patient population.